Document Detail


Effects of renin-angiotensin-aldosterone system blockade on chlorhexidine gluconate-induced sclerosing encapsulated peritonitis in rats.
MedLine Citation:
PMID:  22248199     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Sclerosing encapsulated peritonitis (SEP) is a rare complication of long term peritoneal dialysis. Renin-angiotensin-aldosterone system (RAAS) may play a role in the development of peritoneal fibrosis in CAPD patients. We aimed to evaluate the effect of aliskiren, valsartan, and aliskiren + valsartan therapy on SEP. The study included 30 Wistar albino rats which were divided into five groups: I (Control) SF solution i.p.; II (CG group) chlorhexidine gluconate i.p.; III aliskiren oral plus CG i.p.; IV valsartan oral plus CG i.p.; and V aliskiren oral, valsartan oral and CG i.p. On the twenty-first day, all of the rats were sacrificed. All of the groups were analyzed in terms of peritoneal thickness, degree of inflammation, vasculopathy, neovascularization and fibrosis. Also, the parietal peritoneal tissue samples were evaluated for matrix metalloproteinase 2 (MMP-2) using the ELISA method. Peritoneal thickness and fibrosis scores were lower in the valsartan group compared to the CG group (P < 0.05). Peritoneal fibrosis scores were lower in the aliskiren group compared to CG group (P < 0.05) but no difference was observed between the peritoneal thickness scores of the two groups (P > 0.05). Tissue MMP-2 levels were significantly higher in the CG group compared other groups (P < 0.05). There were no statistically significant differences between the aliskiren, valsartan and aliskiren + valsartan groups according to the tissue MMP-2 levels. Due to the antifibrotic properties of valsartan, it is thought to be a possible choice to prevent SEP development. We found no positive impact of aliskiren or aliskiren + valsartan combination compared to valsartan alone.
Authors:
Gülay Koçak; Alper Azak; Hesna Müzeyyen Astarcı; Bülent Huddam; Gökhan Karaca; Mevlüt Ceri; Murat Can; Mehmet Sert; Murat Duranay
Related Documents :
19540659 - No midterm benefit from low intensity pulsed ultrasound after chevron osteotomy for hal...
743829 - Femoral osteotomy in perthes disease.
17038279 - Flexor hallucis longus tendon transfer for hallux claw toe deformity and vertical insta...
19393939 - Long-term results of remodeling of lateral condylar prominence after lateral closed-wed...
20350819 - Outcome following autogenous soft tissue interpositional arthroplasty for end-stage hal...
7801759 - Chevron osteotomy for hallux valgus not improved by additional adductor tenotomy. a pro...
23363879 - Oral sodium thiosulfate as maintenance therapy for calcific uremic arteriolopathy: a ca...
12082189 - Conventional versus direct stenting in ami: effect on immediate coronary blood flow.
18228109 - Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatmen...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy     Volume:  16     ISSN:  1744-9987     ISO Abbreviation:  Ther Apher Dial     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-01-17     Completed Date:  2012-05-10     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  101181252     Medline TA:  Ther Apher Dial     Country:  Australia    
Other Details:
Languages:  eng     Pagination:  75-80     Citation Subset:  IM    
Copyright Information:
© 2012 The Authors. Therapeutic Apheresis and Dialysis © 2012 International Society for Apheresis.
Affiliation:
Department of Nephrology Pathology General Surgery, Ankara Education and Research Hospital, Ankara, Turkey. gulaykad@hotmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amides / pharmacology*
Angiotensin II Type 1 Receptor Blockers / pharmacology*
Animals
Chlorhexidine / analogs & derivatives
Fumarates / pharmacology*
Matrix Metalloproteinase 2 / metabolism
Peritoneum / pathology
Peritonitis / chemically induced,  metabolism,  pathology*
Rats
Rats, Wistar
Renin / antagonists & inhibitors*
Renin-Angiotensin System / drug effects*
Tetrazoles / pharmacology*
Valine / analogs & derivatives*,  pharmacology
Chemical
Reg. No./Substance:
0/Amides; 0/Angiotensin II Type 1 Receptor Blockers; 0/Fumarates; 0/Tetrazoles; 137862-53-4/valsartan; 502FWN4Q32/aliskiren; 55-56-1/Chlorhexidine; 7004-03-7/Valine; EC 3.4.23.15/Renin; EC 3.4.24.24/Matrix Metalloproteinase 2; MOR84MUD8E/chlorhexidine gluconate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Protein oxidative stress and dyslipidemia in dialysis patients.
Next Document:  Regional citrate anticoagulation in predilution continuous venovenous hemofiltration using prismocit...